| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 35.99% | RBC Capital | $62 → $58 | Maintains | Outperform |
| 09/01/2023 | 64.13% | Stifel | → $70 | Reiterates | Buy → Buy |
| 06/14/2023 | 54.75% | RBC Capital | → $66 | Reiterates | Outperform → Outperform |
| 06/02/2023 | 54.75% | RBC Capital | → $66 | Reiterates | Outperform → Outperform |
| 05/01/2023 | 54.75% | RBC Capital | → $66 | Reiterates | → Outperform |
| 04/18/2023 | 5.51% | Truist Securities | → $45 | Initiates Coverage On | → Hold |
| 02/24/2023 | 24.27% | Baird | $65 → $53 | Downgrades | Outperform → Neutral |
| 08/08/2022 | 64.13% | RBC Capital | $82 → $70 | Maintains | Outperform |
| 05/12/2022 | — | Berenberg | Downgrades | Buy → Hold | |
| 02/25/2022 | 68.82% | Baird | $77 → $72 | Maintains | Outperform |
| 11/06/2020 | 73.51% | BMO Capital | $68 → $74 | Maintains | Market Perform |
| 08/17/2020 | 21.92% | B of A Securities | $44 → $52 | Maintains | Underperform |
| 05/13/2020 | 3.17% | B of A Securities | $52 → $44 | Reiterates | → Underperform |
| 05/08/2020 | 57.09% | RBC Capital | $75 → $67 | Maintains | Outperform |
| 04/08/2020 | 64.13% | Stifel | $73 → $70 | Maintains | Buy |
| 02/20/2020 | 75.85% | Baird | $65 → $75 | Maintains | Neutral |
| 11/22/2019 | 75.85% | RBC Capital | → $75 | Initiates Coverage On | → Outperform |
| 11/22/2019 | 59.44% | Jefferies | → $68 | Initiates Coverage On | → Hold |
| 08/02/2019 | 3.17% | Baird | → $44 | Upgrades | Underperform → Neutral |
| 04/18/2019 | — | Baird | Downgrades | Neutral → Underperform | |
| 03/04/2019 | 5.51% | BMO Capital | $41 → $45 | Maintains | Market Perform |
| 03/01/2019 | — | Goldman Sachs | Upgrades | Neutral → Buy | |
| 12/19/2018 | 3.17% | Baird | $56 → $44 | Maintains | Neutral |
| 11/06/2018 | 19.58% | BMO Capital | $58 → $51 | Maintains | Market Perform |
What is the target price for Stericycle (SRCL)?
The latest price target for Stericycle (NASDAQ: SRCL) was reported by RBC Capital on November 3, 2023. The analyst firm set a price target for $58.00 expecting SRCL to rise to within 12 months (a possible 35.99% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Stericycle (SRCL)?
The latest analyst rating for Stericycle (NASDAQ: SRCL) was provided by RBC Capital, and Stericycle maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Stericycle (SRCL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stericycle, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stericycle was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Stericycle (SRCL) correct?
While ratings are subjective and will change, the latest Stericycle (SRCL) rating was a maintained with a price target of $62.00 to $58.00. The current price Stericycle (SRCL) is trading at is $42.65, which is out of the analyst's predicted range.